PenderFund Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

PenderFund Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,004	Closed	-$172K	–	258
2025 Q4	$172K	Buy	+8,004	New	+$155K	0.03%	137

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

PenderFund Capital Management's AVDL Position: Q1 2026 in Review

PenderFund Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 8,004 shares — an estimated $172K sold.

PenderFund Capital Management first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $172K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

PenderFund Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
PenderFund Capital Management sold 8,004 Avadel Pharmaceuticals shares in Q1 2026, an estimated $172K.
PenderFund Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
PenderFund Capital Management's Avadel Pharmaceuticals position peaked at $172K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on PenderFund Capital Management's 13F filing for Q1 2026, filed 15 May 2026.